Loading
Companies and public funders would jointly pay for standardised experiments that confirm or refute new cancer targets, sharing all results openly, so nobody wastes years on a target that does not hold up.
A consortium modelled on the NIH Accelerating Medicines Partnership and Open Targets in which companies, funders and academic centres pool money to run standardised, blinded target validation (genetic dependency across large cell panels, in vivo knock-out in relevant models, human genetic and expression evidence, tool-compound pharmacology) on nominated academic oncology targets, with all data released publicly. Companies then compete downstream on chemistry and biology. This raises the quality of what enters the valley and removes duplicated validation efforts inside every company.
Shares Patient-derived xenografts, Preclinical results do not reproduce, The valley of death between lab and product.
Shares Patient-derived xenografts, Preclinical results do not reproduce, The valley of death between lab and product.
Shares Set aside 3% of grant budgets to replicate findings before translation, Patient-derived xenografts, The valley of death between lab and product.
Shares DepMap (Cancer Dependency Map), CRISPR functional genomics, Preclinical results do not reproduce.
Shares DepMap (Cancer Dependency Map), Patient-derived xenografts, CRISPR functional genomics.
Shares Patient-derived xenografts, CRISPR functional genomics, Preclinical results do not reproduce.
Shares Patient-derived xenografts, Secrecy and intellectual property block collaboration, Preclinical results do not reproduce.
Shares CRISPR functional genomics, Preclinical results do not reproduce, The valley of death between lab and product.